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Abstract
Background: The poor recognition and related underdiagnosis of COPD contributes to an underestimation of
mortality in subjects with COPD. Data derived from population studies can advance our understanding of the true
burden of COPD. The objective of this report was to evaluate the impact of COPD on mortality and its predictors
in a cohort of subjects with and without COPD recruited during the twenty first century.
Methods: All subjects with COPD (n = 993) defined according to the GOLD spirometric criteria, FEV1/FVC < 0.70,
and gender- and age-matched subjects without airway obstruction, non-COPD (n = 993), were identified in a
clinical follow-up survey of the Obstructive Lung Disease in Northern Sweden (OLIN) Studies cohorts in 2002-2004.
Mortality was observed until the end of year 2007. Baseline data from examination at recruitment were used in the
risk factor analyses; age, smoking status, lung function (FEV1 % predicted) and reported heart disease.
Results: The mortality was significantly higher among subjects with COPD, 10.9%, compared to subjects without
COPD, 5.8% (p < 0.001). Mortality was associated with higher age, being a current smoker, male gender, and COPD.
Replacing COPD with FEV1 % predicted in the multivariate model resulted in the decreasing level of FEV1 being a
significant risk factor for death, while heart disease was not a significant risk factor for death in any of the models.
Conclusions: In this cohort COPD and decreased FEV1 were significant risk factors for death when adjusted for
age, gender, smoking habits and reported heart disease.
Background
Chronic Obstructive Pulmonary Disease (COPD) is
recognized as a major public health problem with an
increasing morbidity and mortality. It has been forecasted
that COPD will be ranked the fourth burden of disease
worldwide by year 2030 [1]. The prevalence of COPD is
most often reported in the range of 6-10% of the total
adult population [2], it is strongly correlated to smoking
and age, and about 50% of elderly smokers fulfil the
spirometric criteria of COPD [3]. Population studies have
shown that a large majority of COPD patients have mild-
to-moderate disease [4].
The underdiagnosis of COPD is well-known. Only
about a third of all cases with COPD have been recog-
nized by the health care [3-6], and the proportion of
undiagnosed cases decreases with increasing disease
severity [4]. Most reports on mortality in COPD are
based on death certificates and hence, due to the under-
diagnosis, the true impact of COPD on mortality is prob-
ably greatly underestimated. There are only few reports
on mortality in COPD based on population studies. In a
follow-up over up to 22 years of a large general popula-
tion cohort in the USA, the NHANES I recruited 1971-
75 follow-up in 1992 included totally 923 cases of COPD.
T h eo v e r a l lm o r t a l i t yi nC O P Dw a s4 4 %a n di ns e v e r e
COPD 71%. Subjects with mild, moderate and severe
COPD, and subjects with restrictive lung function
impairment, had an increased risk for death [7]. There is
a 30-year follow up of a large population sample from
southern Sweden, both smokers and non-smokers with
COPD had a significantly increased risk for death [8].
The first cohort of the Obstructive Lung Disease in
Northern Sweden (OLIN) studies, was recruited in 1985-
86, and in a recently published 20-year follow-up an
overall mortality of 54% in subjects with COPD was
reported, while the mortality in severe and very severe
COPD at entry was 81% [9].
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expressed as FEV1, is known to predict death [10,11].
Reduced FEV1 has also been reported to be a marker of
cardiovascular death [12]. However, due to the underdiag-
nosis and lack of longitudinal epidemiological data, the
present impact of COPD identified through spirometric
screening in the general population on mortality consider-
ing the influence of other factors such as cardiovascular
co-morbidity has been ill-described.
Within the OLIN studies, cross-sectional and longitu-
dinal data on respiratory diseases, including lung func-
tion, have been collected in several cohorts recruited
from the general population at different occasions ever
since 1985 [3,4,9,13,14]. Previously recruited adult OLIN-
cohorts were invited to a clinical follow-up in 2002-2004,
and from the participants all subjects with COPD were
identified together with age and gender matched subjects
without airway obstruction [15]. The aim of the present
paper is to report overall mortality in this cohort based
on mortality data collected up to the end of 2007, and to
evaluate the impact of COPD, level of FEV1,g e n d e r ,
smoking habits and heart disease on mortality.
Methods
Study design and Study population
The recruitment of the study cohort and the study design
has been reported previously [15]. In 2002-2004 four pre-
viously identified population based adult OLIN cohort
(one from the eighties and three from the nineties) were
invited to re-examination including structured interview
and spirometry. When the examinations were completed
all subjects with COPD according to The Global Initiative
for Chronic Obstructive Lung Disease (GOLD) spiro-
metric criteria [16], FEV1/FVC < 0.70, were identified (n =
993) together with an age- and gender matched reference
sample with non-obstructive lung function. This cohort,
all together 1986 subjects (1084 men; 902 women) has
since 2005 been invited to yearly examinations including
lung function testing and a structured interview. The
study was approved by the Regional Ethics Committee at
University Hospital of Northern Sweden and Umeå
University.
Data collected in 2002-2004 were used for baseline char-
acteristics. The observation time is from the date of exam-
ination at recruitment until the end of year 2007, and the
mean follow-up time can be approximated to four years.
Mortality data during the period, including date of death,
were collected from the national mortality register.
Baseline measurements
Structured interview
A previously validated questionnaire was administered
via a structured interview [4,13,14]. Smoking habits
were classified into the following groups: non-smokers,
ex-smokers (stopped at least one year before the base-
line visit) and current smokers. The variable ‘heart dis-
ease’ includes self-reported angina pectoris, previous
coronary artery bypass surgery, previous percutaneous
coronary intervention, myocardial infarction or heart
failure.
Spirometry
The lung function tests were performed using a dry spi-
rometer, Mijnhardt Vicatest 5 by following the ATS guide-
lines [17]. Vital capacity (VC) was defined as the best value
of forced vital capacity (FVC) and slow vital capacity
(SVC). A reversibility test was performed when the ratio
of FEV1/VC was < 70% or if FEV1 was < 90% of predicted
value. The Swedish normal values by Berglund et al were
used [18]. When calculating the FEV1/VC ratio and defin-
ing the severity of COPD, the largest value of FEV1 as well
as of VC was used.
Body Mass Index
Weight and height were recorded before the lung function
test. Body Mass Index (BMI) was calculated: weight (kg)/
(height (m)*height (m)) and was classified into normal
(range 20 - < 25), underweight (< 20), overweight (range
25 - < 30) and obesity (≥ 30).
Classification of COPD
Spirometric classification of COPD according to GOLD,
FEV1/VC < 0.7, was used. The classification of severity
of COPD includes for stages based on FEV1 % predicted.
Stage I FEV1 ≥ 80% predicted
Stage II FEV1 ≥50 and < 80% predicted
Stage III FEV1 ≥30 and < 50% predicted
Stage IV FEV1 < 30% predicted
Statistical analysis
Statistical calculations were made using the Statistical
Package for the Social Sciences (SPSS) software version
PASW 18.0 and Microsoft Excel 2007. The sample com-
prised of six age groups. Crude mortality rates based on
data collected by the end of 2007 were analysed by gender,
disease status (COPD or non-COPD), and selected base-
line descriptors (smoking habits, BMI and heart disease).
The chi-squared test was used for bi-variate comparisons
and to test for trends. A p-value of < 0.05 was regarded as
significant. The hazard function of death, which describes
the momentary risk, was estimated by use of Poisson
regression depending on several variables. The follow-up
period of each individual was divided into intervals of the
length 0.1 years, when the contribution to the log likeli-
hood function was calculated. The variables age and obser-
vation time was updated at each interval. For each risk
variable of death, we calculated the hazard ratio (HR) of
an increase of 1 unit and the corresponding 95% confi-
dence interval (CI). Three different models were studied
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time, gender, heart disease and disease status (COPD or
non-COPD) [2] age, observation time, gender, disease sta-
tus (COPD or non-COPD), heart disease, and FEV1 per-
cent predicted, [3] age, observation time, gender, heart
disease, and FEV1 percent predicted. For the models [1]
and [3] analyses were also done including the variable
smoking habits categorized as non-smoker, ex-smoker and
smoker. A possible interaction between COPD and heart
disease was tested in model 1 and an interaction between
heart disease and FEV1 in the later models. Multivariable
analyses were also conducted in models including the co-
variates BMI and smoking categories. Furthermore, we
used a Poisson regression model including spline functions
of FEV1, which allowed the hazard function to vary with a
greater freedom and still correspond to a smooth curve. A
simple model includes just one coefficient of FEV1 and
that restrict the shape of the curve.
Results
Study population
Baseline characteristics of the study population at
recruitment are shown in table 1. All together, 36.2% of
the subjects were non-smokers, 40.5% ex-smokers and
23.3% current smokers. There were more smokers and
fewer non-smokers in subjects with COPD compared to
in non-COPD. The prevalence of self-reported heart dis-
ease was similar in COPD and non-COPD (p = 0.429).
At recruitment the distribution by disease severity
among subjects with COPD was 52.2%, 40.3%, 6.1%, and
1.4%, in GOLD stages I, II, III, and IV respectively.
Mortality
In total, 166 subjects, 8.4% (9.6% men; 6.9% women, p =
0.029), had died until the end of 2007. Crude mortality
data are shown in table 2. The mortality was signifi-
cantly higher among subjects with COPD, 10.9% (n =
108), compared to non-COPD subjects, 5.8% (n = 58) (p
< 0.001). No one had died in the youngest age group
(born after 1961) but thereafter the mortality increased
by increasing age both among subjects with and without
COPD. Comparing COPD and non-COPD, the mortality
was significantly higher among subjects with COPD in
the three oldest age groups (born 1920 and before,
1921-1930 and 1931-1940). In smokers and ex-smokers,
in subjects with BMI > 25, and among those without
concomitant heart disease, the mortality was signifi-
cantly higher in subjects with COPD as compared to
non-COPD. There was no significant difference in mor-
tality between the COPD and non-COPD groups among
non-smokers, subjects with underweight or normal
weight (BMI < 20 or BMI 20-25), and among subjects
with reported heart disease.
Analyses of risk factors for death
I nam u l t i v a r i a t em o d e l ,C O P Dw a sas i g n i f i c a n tr i s k
factor for death (HR 2.06, CI 1.49-2.85), and so was
increasing age (HR 1.08, CI 1.07-1.10), male gender (HR
1.52, CI 1.10-2.10) and heart disease (HR 1.43, CI 1.01-
2.02). When the variable smoking habits was added to
the model, heart disease did not reach statistical signifi-
cance, but close to (HR 1.42, CI 1.00-2.01) (table 3).
BMI did not contribute significantly and ex-smoker did
not significantly differ for non-smoker (not shown in
tables). No significant interaction was found between
heart disease and COPD or between FEV1 and heart dis-
ease, thus COPD was a significant risk factor for death
irrespectively of reported heart disease at start of the
observation period. Nor was there any significant inter-
action between COPD and smoking, i.e. COPD was
associated with an increased mortality independent if
smoking or not. In a model including both COPD and
FEV1, COPD lost its significance as a risk factor for
death in the presence of FEV1 in the statistical model.
Figure 1 illustrates an example of the hazard function of
death in relation to FEV1 in a 70 year old man after an
observation time of two years. The model including a
spline function indicates that the effect of FEV1 on mor-
tality is more outstanding in subjects with FEV1 < 50%
of predicted values than what can be shown by using a
simpler model. Using FEV1 instead of COPD in the
multivariate model, decrease in level of FEV1 at baseline
was an independent significant risk factor for death
together with increasing age, male gender and current
smoking while heart disease did not reach statistical sig-
nificance (table 4).
Table 1 Study population, basic characteristics at the
recruitment (2002-2004)
Category Variable COPD
(n = 993)
No COPD
(n = 993)
Gender (n) Men 543 541
Women 450 452
Age group, year of birth (n) -1920 113 113
1921-30 146 147
1931-40 374 358
1941-50 267 282
1951-60 73 73
1961- 20 20
Smoking (%) Non smoker 24.1 47.9
Ex smoker 41.5 39.6
Smoker 34.4 12.6
BMI (%) < 20 3.9 1.6
20 - < 25 40.8 35.6
25 - < 30 39.9 46.5
≥ 30 15.3 16.4
Heart disease (%) Yes 16.9 14.6
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The strength and newsworthy of the current study is the
up-to date report on the impact of COPD on mortality.
The identification of the study population and the obser-
vation time took place during the twenty first century
when treatment for COPD as well as cardiovascular dis-
ease was recommended according to modern and current
guidelines. Further, the distribution of disease severity
among subjects with COPD in the cohort was representa-
tive for what has been reported for the general population,
comprising of more than 90% of patients in GOLD stages
I and II [4]. COPD was a significant risk factor of
increased mortality in this topical epidemiological context.
There are only a few previously published population
based studies on mortality in subjects with COPD
defined according to currently accepted spirometric cri-
teria [7-9,19]. As referred to in the introduction, these
study populations were recruited during the nineteen-
seventies and eighties. The mortality data in these studies
Table 2 Crude mortality in percent among subjects with COPD and controls (FEV1/VC < 0.70 and FEV1/VC > 0.70,
respectively), by gender, age-group (year of birth), smoking habits, BMI and reported heart disease
Category Variable COPD (n = 993) p-value
1 No COPD (n = 993) p-value
2 p-value
3
Gender Men 12.3 6.9 0.002
Women 9.1 0.109 4.6 0.138 0.008
Age group, born -1920 32.7 15.9 0.003
1921-30 18.4 9.6 0.030
1931-40 9.1 4.7 0.020
1941-50 3.0 3.2 0.883
1951-60 2.8 0
1961- 0 0
Smoking Non smoker 8.3 5.3 0.125
Ex smoker 12.2 6.7 0.008
Smoker 11.3 0.314 4.8 0.617 0.036
BMI < 20 25.6 25.0 0.960
20 - < 25 9.9 6.8 0.131
25 - < 30 9.6 4.8 0.006
≥ 30 12.5 0.016 4.3 0.004 0.009
Heart disease No 9.1 4.5 < 0.001
Yes 19.6 < 0.001 12.9 < 0.001 0.102
1Comparing within each category among subjects with COPD
2Comparing within each category among controls (no COPD)
3Comparing COPD and controls (no COPD) by each variable
Table 3 Risk factors for death expressed as Hazard Ratio
(HR) and 95% Confidence Interval (CI) including the co-
variates age, time since recruitment, gender, smoking
habits, COPD and heart disease
Variable HR 95% CI p-value
Age
1 1.09 1.07-1.11 < 0.001
Time since recruitment
1 1.03 0.95-1.12 0.504
Gender
2 1.43 1.02-2.00 0.040
Ex-smoker
3 1.29 0.87-1.92 0.203
Smoker
3 2.01 1.27-3.19 0.003
Heart disease
4 1.42 1.00-2.01 0.051
COPD
4 1.77 1.26-2.49 0.001
1One unit change represents one year
2Reference group: female gender
3Reference group: non smoker
4Reference group: not reporting heart-disease respectively non-COPD
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Figure 1 Hazard function of death, expressed as incidence of
death per 1000 person years, by FEV1 percent predicted in a
70 year old man after two years observation time in a model
using a spline function and a simple model.
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to more than twenty years, thus a healthy survivor effect
must be taken into account when evaluating these data.
Further, updated guidelines during the last decade for
treatment of not only COPD, but also cardiovascular dis-
ease, have improved the prognosis compared to thirty
years ago. Consequently, the starting point, the time and
the length of the observation time are of importance
when evaluating and comparing mortality data not only
in COPD but also other diseases. There are mortality
data collected in two large clinical trials started during
the nineties with an observation time over three and four
years respectively, the TORCH and the UPLIFT studies.
The all-cause mortality reported from the TORCH-study
was 14.3% [20] in a population with moderate- to severe
COPD (FEV1 < 60 percent of predicted). In the UPLIFT-
study [21] subjects with a post-bronchodilator FEV1 <7 0
percent of predicted were included, and the crude mor-
tality in the total population was 15.4% at the end of the
treatment period. After the approximately four year’s
observation time, similar to the UPLIFT, the mortality
w a s1 0 . 9 %a m o n gs u b j e c t sw i t hi nC O P Di no u rs t u d y .
However, the UPLIFT-cohort had a lower baseline mean
FEV1 compared with our study, further, as most clinical
studies the UPLIFT-study included a selected population
with regard not only to lung function but also to other
factors such as age and co-morbidity. Further, in a 13-
year follow-up of the ISOLDE study [22], the mortality
was 56% in the study population including subjects with
moderate- to severe COPD.
The reported mortality in this study can be considered
up-to-date as both the identification of the study popula-
tion and the observation time took place after the turn of
the century, where modern and current guidelines for
treatment have been well established in Sweden. Subjects
with COPD in the cohort are considered representative
for the general population with regard to distribution by
disease severity [4]. There are, to the best of our knowl-
edge, no other published similar studies. Further
s t r e n g t h so ft h es t u d ya r et h el a r g es i z eo ft h eC O P D -
population, comparable to that of the NHANES I [7], the
accuracy of mortality data and that there was no loss of
follow-up. However, possible limitations are the com-
paratively short time of follow up and that information
on heart disease was self-reported and not collected from
medical records. Another limitation is that the classifica-
tion of COPD was strictly madeb ys p i r o m e t r i cc r i t e r i a
without regard to respiratory symptoms. This has to be
considered when interpreting the data, as respiratory
symptoms are known to affect the prognosis in mild/
moderate COPD [23]. Further, the non-COPD popula-
tion did also include subjects with restrictive lung func-
tion impairment, even though the ability for a dynamic
spirometry to identify restrictive lung function can be
questioned. The reasons for a restrictive pattern on
dynamic spirometry are highly heterogeneous and reflect
different underlying disorders as idiopathic pulmonary
fibrosis, thoracic deformities, obesity, pleural effusion,
cardiac insufficiency and neuromuscular diseases.
As expected, increasing age was the most prominent risk
factor for death. Among all subjects born < 1940, the pro-
portion of deceased was significantly larger among sub-
jects with COPD. The use of a fixed ratio to define airway
obstruction, FEV1/FVC < 0.70, has been discussed with
regard to identifying clinically relevant COPD among
elderly [24], but the results from our study indicate that
the fixed ratio identifies a population with significantly
increased mortality also among subjects older than
80 years. There is a recent report on 5-year mortality
among subjects aged > 65 years, where COPD according
to GOLD was not associated with increased mortality
among those older then 75 years [25]. However, the study
population was recruited was from an out patient clinic,
and can thus not be considered to reflect COPD in the
general population.
When FEV1 was included in the multivariate analyse
model, COPD was no longer a significant risk factor for
death, but the level of FEV1, reflecting disease severity at
recruitment, was related to mortality. Our data exemplify
that a decrease in FEV1 in the range of 100 to 50 percent
of predicted will continuously increase the risk for death,
and further, illustrated by Fig u r e1 ,ad r a m a t i ci n c r e a s e d
risk for death occurs when FEV1 continues to decrease
below 50 percent of predicted. It is well-known that
tobacco exposure contributes to the development of both
COPD and cardiovascular diseases, and cardiovascular
death is the most common cause of death in the world.
In a multivariate model heart disease was a significant
risk factor for death just as COPD, age and male gender,
however, when smoking habits were added to the model
Table 4 Risk factors for death expressed as Hazard Ratio
(HR) and 95% Confidence Interval (CI), including the co-
variates age, time since recruitment, gender, heart
disease, smoking habits and FEV1 percent predicted
Variable HR 95% CI p-value
Age
1 1.09 1.07-1.11 < 0.001
Time since recruitment
1 1.03 0.95-1.12 0.478
Gender
2 1.45 1.03-2.03 0.034
Ex-smoker
3 1.26 0.85-1.86 0.259
Smoker
3 1.91 1.21-2.99 0.005
Heart disease
4 1.36 0.96-1.93 0.084
FEV1 percent predicted
5 0.98 0.97-0.99 < 0.001
1One unit change represents one year
2Reference group: female gender
3Reference group: non-smoker
4Reference group: not reporting heart-disease
5The unit change represent one percent unit
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risk for death while male gender and reported heart dis-
ease each increased the risk on a similar level, approxi-
mately 40%, even though heart disease did not reach
statistical significance as a risk factor. Impaired lung
function is a known risk factor for death [10,11] and
according to our results the risk for death in subjects
with COPD, when adjusted for confounders including
presence of heart disease, was increased by about 75%
compared to in subjects without COPD. Maybe the
impact of current treatment guidelines of cardiovascular
disease has reduced mortality contributing to the border-
line significance of heart disease as a risk factor while we
found COPD and impaired lung function still being
strong and significant risk factors for death.
Besides smoking, BMI is a known prognostic factor in
COPD, and increased loss of weight is associated with a
higher mortality in COPD [26,27]. In this study BMI
could not predict mortality; however, longitudinal data
on weight loss were not included. An important message
is also the benefit of smoking cessation, i.e. being an ex-
smoker did not differ significantly from non-smokers
with regard to risk for death, while current smoking
roughly doubled the risk for death. According to a 9-year
follow-up from the ECRHS non-smoking non-sympto-
matic young adults with mild/moderate COPD do not
have worse outcome than subjects without COPD [23].
Further follow-up of our cohort will give us correspond-
ing data from middle aged and elderly subjects with
mild/moderate COPD. There was surprisingly no signifi-
cant difference in prevalence of heart disease in subjects
with and without COPD, however, the dominance of
GOLD stage I and II in the COPD-cohort might contri-
bute to this finding.
Conclusions
In this recently identified cohort, where COPD was
mostly represented by GOLD stages I & II, COPD, age
and current smoking were the strongest risk factors for
death. Male gender and reported heart disease were also,
and on a similar level, associated to an increased risk for
death, even though heart disease did not reach statistical
significance. The results further indicate that not only
COPD but also impaired lung function, expressed as
level of FEV1, is a significant risk factor for death inde-
pendent of confounders as age, gender, smoking habits
and heart disease.
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